NuvaRing Pulmonary Embolism Lawsuit Alleges That a Colorado Woman Sustained Pulmonary Emboli Due to Use of NuvaRing Contraceptive, Reports Alonso Krangle
New York, NY (PRWEB) September 08, 2013 -- Alonso Krangle’s attorneys have recently filed a NuvaRing pulmonary embolism lawsuit on behalf of a woman from Colorado. This case (Case No. 2:13-cv-03060-SDW-MCA) was filed on May 13, 2013 in the U.S. District Court of New Jersey and specifically names the defendants to be Organon USA, Inc. and Merck & Co., Inc.
According to court documents, the plaintiff began using NuvaRing in April 2011. Within a few months of using this contraception, the plaintiff reportedly developed chest pain and shortness of breath, which led her to seek medical care for an official diagnosis. After undergoing a CT scan, the plaintiff was told that she had developed multiple blood clots (emboli) in her lungs, with the official diagnosis being pulmonary embolism. Following this diagnosis, the plaintiff was hospitalized for nearly a week and was placed on anticoagulation therapy, including Warfarin. While the plaintiff is currently still on this anticoagulation therapy, she has also had to undergo regular follow-up care to monitor her health.
Alonso Krangle’s experienced defective drug attorneys are dedicated to standing up for victims’ rights and holding even the largest corporations accountable for their potentially dangerous medications. We offer free NuvaRing pulmonary embolism lawsuit evaluations to those who have sustained serious injuries, such as blood clots and pulmonary embolisms, that could be linked to the use of NuvaRing. To discuss a potential NuvaRing pulmonary embolism lawsuit claim with one of the compassionate NuvaRing pulmonary embolism lawsuit lawyers at Alonso Krangle LLP, please contact us at 1-800-403-6191 or visit our website, FightForVictims.com.
Allegations In The NuvaRing Pulmonary Embolism Lawsuit
This NuvaRing pulmonary embolism lawsuit alleges that the plaintiff’s use of NuvaRing was responsible for her injuries. Additionally, this case contends that Organon and the other defendants were aware of but failed to warn the public about the fact that NuvaRing is linked to a higher risk of blood clot-related complications than oral contraceptives. Specifically, according to the complaint, this NuvaRing pulmonary embolism lawsuit alleges that the defendants marketed NuvaRing as a safe and effective contraceptive without warning women about the serious risks of potentially life-threatening injuries reportedly linked to NuvaRing use.
Blood Clot Injuries Linked NuvaRing Use
The link between NuvaRing use and the development of serious blood clot disorders like pulmonary embolism has been reported by many medical researchers within recent years. Specifically, in 2012, a study published in the New England Journal of Medicine reported that vaginal rings like NuvaRing could increase women’s risk of developing blood clots by nearly three times, when compared to the risk associated with older birth control pills. (nejm.org/doi/full/10.1056/NEJMoa1111840) Another study published in the May 2012 British Medical Journal reported that women’s risk of developing blood clots increased by more than 6 times when using vaginal rings like NuvaRing, as opposed to birth control pills.
(bmj.com/content/344/bmj.e2990#alternate)
The alleged serious risks associated with NuvaRing use seem to be backed up by information from the FDA’s Adverse Events Reporting System (AERS), which has received more than 5,350 reports of serious adverse events related to NuvaRing use since the drug was first introduced in 1997 (though FDA approval was not granted until 2001). Among the most commonly reported adverse effects associated with NuvaRing use were more than 1,170 incidents of pulmonary embolism and more than 1,150 incidents of thrombosis and deep vein thrombosis. According to the FDA AERS, more than 30 percent of women who reported NuvaRing complications had to be hospitalized due to the severity of their injuries, and approximately 3 percent of NuvaRing complications resulted in death.
(adverseevents.com/drugdetail.php?AEDrugID=4584&BrandName=NUVARING)
About Alonso Krangle LLP And Filing A NuvaRing Pulmonary Embolism Lawsuit
Alonso Krangle’s experienced defective drug attorneys are dedicated to standing up for victims’ rights and holding even the largest corporations accountable for their potentially dangerous medications. We offer free NuvaRing pulmonary embolism lawsuit evaluations to those who have sustained serious injuries, such as a deep vein thrombosis, blood clots and pulmonary embolisms, that could be linked to the use of NuvaRing. To discuss a NuvaRing pulmonary embolism lawsuit claim with one of the compassionate NuvaRing pulmonary embolism lawsuit lawyers at Alonso Krangle LLP, please contact us at 1-800-403-6191 or visit our website, FightForVictims.com.
Andres Alonso and David Krangle, attorneys with almost 40 years of collective legal experience, have focused their law practice on handling significant personal injury cases, defective drug and medical device litigation, construction site accidents, nursing home abuse, medical negligence, qui tam/whistleblower actions and consumer fraud cases. Alonso Krangle LLP is headquartered in Long Island, New York, with offices in New York City, and New Jersey.
For more information about Alonso Krangle or to join the fight and be a part of our team, please contact us at 1-800-403-6191 or visit our website, FightForVictims.com.
David Krangle, Alonso Krangle LLP, http://www.fightforvictims.com, +1 800-403-6191, [email protected]
Share this article